U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07918820) titled 'Clinical Application Research Plan for Fully Automated Chemiluminescent Immunoassay Reagents' on Nov. 01.
Brief Summary: For the remaining serum, plasma, urine or other body fluid samples from clinical tests, chemiluminescence immunoassay reagents are used (covering eleven types of markers such as infectious diseases, tumors, hormones, thyroid function, liver fibrosis, inflammatory factors, diabetes, anemia, cardiovascular and cerebrovascular diseases, thrombotic diseases, and reproductive health). The main current platforms in this department are: Antuo (for infectious diseases, liver fibrosis, and reproductive health markers), Abbo...